Velaglucerase Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Velaglucerase alfa: From Gaucher Disease to Steel Syndrome
One-Sentence Summary
Velaglucerase alfa is an enzyme replacement therapy whose approved indication is Gaucher disease (type 1), where it substitutes for deficient glucocerebrosidase. The TxGNN model predicts it may be effective for Steel syndrome, a COL27A1-related skeletal dysplasia, but this prediction is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as a likely knowledge-graph artifact rather than a mechanistically grounded hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gaucher disease (type 1) — inferred from evidence-pack rationale text; not independently confirmed by regulatory data |
| Predicted New Indication | Steel syndrome |
| TxGNN Prediction Score | 96.99% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available ([Data Gap] in the evidence pack). Based on the information that is present, velaglucerase alfa is a recombinant human glucocerebrosidase used as enzyme replacement therapy, and its efficacy in Gaucher disease — a lysosomal storage disorder caused by glucocerebrosidase deficiency — is well established.
Steel syndrome, however, is a skeletal dysplasia caused by mutations in COL27A1, a collagen gene. It has no known overlap with the glycosphingolipid-metabolism pathway that glucocerebrosidase acts on. The evidence pack’s own mechanistic assessment states this explicitly: the high TxGNN score is likely an artifact of “rare genetic disease” node clustering in the knowledge graph, rather than a reflection of shared biology.
This pattern repeats across the other nine ranked candidates in the evidence pack: several (hypophosphatasia, growth hormone insensitivity syndrome, proximal myopathy with extrapyramidal signs) are flagged as having no plausible pathway overlap; a few (Wolman disease, cholesteryl ester storage disease) share only a broad “lysosomal storage disease / enzyme replacement therapy” class-level similarity without substrate specificity for glucocerebrosidase; and two (esophageal varices, with and without bleeding) are actually downstream complications of Gaucher disease itself rather than independent new indications. None of the ten candidates is supported by a mechanistic rationale strong enough to justify progression without further validation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Velaglucerase alfa currently has no EU marketing authorization on record in this evidence pack (0 authorizations, market status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
Note: Label warnings/contraindications data collection is flagged in the evidence pack as a blocking data gap and has not yet been retrieved from the regulatory source.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten TxGNN-predicted indications are L5 (model-prediction-only, no supporting clinical trials or literature), and the evidence pack’s own mechanistic analysis indicates most — including the top-ranked Steel syndrome — are likely knowledge-graph clustering artifacts without biological plausibility. Combined with a blocking gap in regulatory safety data, there is no basis to proceed at this time.
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (blocking gap, DG001)
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature (DG002)
- Independent mechanistic review of the top candidates to distinguish genuine signal from graph-embedding artifact before any evidence-collection effort is invested
- If any candidate is prioritized, targeted literature/clinical-trial searches to establish at least L3–L4 evidence before further scoring
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.